Nucl Med Mol Imaging.  2022 Oct;56(5):259-562. 10.1007/s13139-022-00761-7.

68Ga‑DOTATATE Avid Metastatic Vertebral Renal Cell Carcinoma in the Setting of von Hippel‑Lindau Syndrome

Affiliations
  • 1Section on Medical Neuroendocrinology, Developmental Endocrine Oncology and Genetics Affinity Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Dr., MSC‑1109, Bldg. 10, CRC, Room 1E‑3140, Bethesda, MD 20892‑1109, USA
  • 2Department of Pathology, University of Chicago Medical Center, Chicago, IL, USA
  • 3Invitae, Medical Affairs, San Francisco, CA, USA
  • 4Department of Medicine, Section of Hematology/Oncology and Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA
  • 5Department of Medicine, Division of Hematology, Oncology, and Palliative Care & Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI, USA
  • 6Department of Radiology, Clinical Center, NIH, Bethesda, MD, USA

Abstract

Although rare, a metastatic renal cell carcinoma could present with 68Ga-DOTATATE avidity. A 66-year-old man with von Hippel-Lindau syndrome (VHL) presented with 68Ga-DOTATATE uptake in the pancreatic head, splenic hilar region, and multiple osseous sites, including the right lateral portion of the T9 vertebrae. Biopsy of the T9 lesion confirmed metastatic renal cell carcinoma. Various VHL-associated cancers may display 68Ga-DOTATATE avidity, which can change and guide clinical decisions for the patient.

Keyword

von Hippel-Lindau; 68Ga-DOTATATE; Renal cell carcinoma; Pheochromocytoma; Paraganglioma; Somatostatin receptors
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr